32 results about "Bone morphogenetic protein 7" patented technology

Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and / or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s).

Protein formulations that can be lyophilized and are stable in organic solvents. The formulations contain bone morphogenetic proteins, lyoprotectants, and oxidation / reduction stabilizers. Optionally, the formulations may also contain solvent environment stabilizers. The protein formulations can be incorporated into a polymeric matrix to make medical devices for delivering the protein, and coatings for medical devices.

The invention relates to a 3D print scaffold material and a preparation method and application thereof and particularly relates to a 3D print scaffold material for periodontal tissue reconstruction and a preparation method and thereof. The material comprises the following components: a stromal cell-derived factor-1 (stromal cell-derived factor-1, SDF-1) and a bone morphogenetic protein 2 (Bone Morphogenetic Proteins, BMPs). By adopting two functional molecules of SDF-1 and BMP2, endogenous stem cells are collected into a periodontal defect area, osteogenic differentiation is accelerated, periodontal tissue regeneration is accelerated, meanwhile, an individual bionic degradable polymer scaffold is designed on the basis of 3D printing, and the external form and the internal microstructure of the material is precisely controlled through a computer.

The invention belongs to the field of a biomedical material, which is mainly applied to the preparation of a compound dosage form both of bone morphogenetic protein 2 active peptide and hydroxyapatite, wherein a sequence of the bone morphogenetic protein 2 active peptide is represented by SEQ ID NO: 1-10. A preparation method provided by the invention comprises the following steps: dissolving the bone morphogenetic protein 2 active peptide into normal saline or 5% of glucose solution, and then adding a hydroxyapatite support, combining the bone morphogenetic protein 2 active peptide on the surfaces of the hydroxyapatite particles to obtain the necessary compound dosage form both of the bone morphogenetic protein and hydroxyapatite after centrifugal separation, washing and drying, so as to obtain a human hard tissue repair material provided by the invention.

A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.

The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and / or BMPR-II, in an amount sufficient to for inhibiting or reducing vascular inflammation by interfering with binding of bone morphogenic protein or a fragment thereof to bone morphogenic protein receptors. Exemplary BMP antagonists include polypeptides having an eight-, nine-, or ten-membered ring cystine knot structure. Representative BMP antagonists include, but are not limited to the CAN family of proteins, the chordin family that includes chordin and ventroptin, and noggin.

A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and / or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and / or osteoarthritis.

The invention discloses an application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis and belongs to the field of biomedicine. Screened drug types comprise: bone morphogenetic protein-4 formation inhibitor, bone morphogenetic protein-4 antagonistic, bone morphogenetic protein-4 receptor antagonists and bone morphogenetic protein-4 downstream signal antagonistic. The invention also relates to an application of the drugs in preparation of medicines for resisting cardiac hypertrophy, heart failure and arrhythmia. Researches have found that bone morphogenetic protein-4 can induce myocardial hypertrophy, apoptosis and cardiac fibroblast collagen secretion increase, lead to occurrence of cardiac hypertrophy, heart failure and arrhythmia. However, drugs for antagonism of bone morphogenetic protein-4 and its cell signaling pathway can be used to inhibit occurrence of cardiac hypertrophy, inhibit cardiac fibrosis and minimize occurrence of cardiac cell death and arrhythmia. The invention provides a theoretical basis for realizing high-flux medicine screening, and is of practical guiding significance.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

The present invention provides bone morphogenetic protein receptor (BMPR) binding agents, such as antibodies, and compositions comprising said binding agents. The binding agents are useful to treat diseases such as cancer.

The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition by administering a neurotrophic factor and an inhibitor of pro-gliogenic bone morphogenetic proteins. Also disclosed is a method of suppressing astrocyte generation and inducing neuronal production in a subject, a method of treating a neurologic condition, and a method of suppressing glial scar formation in a subject by administering an inhibitor of pro-gliogenic bone morphogenetic proteins. Finally, the present invention involves a method of introducing a heterogeneous protein into a subject's brain and spinal cord by introducing a nucleic acid molecule encoding the heterogeneous protein introduced into the subject's ependyma, permitting the protein from the nucleic acid molecule to be expressed within the subject's ependyma, and permitting the expressed protein to migrate within the subject's brain and spinal cord.

The invention discloses a medicament for preventing and treating disuse osteoporosis and a preparation method thereof. The medicament is prepared from the following raw medicaments: prepared rhizome of rehmannia, teasel root, mistletoe, angelica, peach seeds, safflower, achyranthes root, drynaria rhizome and licorice, which form a kidney tonifying and blood activating formula. The medicament can further comprise astragalus root and pseudostellaria heterophylla, so as to obtain a qi tonifying, kidney tonifying and blood activating formula. The medicament can improve the bone metabolism of disuse osteoporosis rats, reduce the content of ALP (alkaline phosphatase) or BAP (bone alkaline phosphatase), obviously improve the content of Ca, BGP (bone calcium protein), BMP-2 (bone morphogenetic protein 2), HOP (urinary hydroxyproline), HOP / Cr and TRAP (tartrate-resistant acid phosphatase), reduce the content of TNF-alpha (tumor necrosis factor-alpha), IL-4 (interleukin-4) and IL-6 (interleukin-6), promote the proliferation of mesenchymal stem cells, effectively improve the activity of BALP (bone alkaline phosphatase), increase bone formation, benefit to treating the disuse osteoporosis, obviously promote the proliferation of osteoclasts, improve bone formation, reduce bone absorption and promote the increase of bone mass, and has a certain prevention effect on the disuse osteoporosis.

Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and / or osteoarthritis.

Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.

Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.

The invention relates to the bone tissue gene engineering technical sphere, which in detail to recombinant vector of bone formation protein gene 4, the virus granule which converted and packed by said vector and preparing tissue engineering bone by applying the virus granule and its application. The invention is characterized in that: successfully constructing pLEGFP-hBMP-4 reverse transcript viral vectors by taking pLEGFP as the reverse transcript viral vectors; getting LEGFP-hBMP-4 and LEGP reverse transcript viral vectors by packing the cell PA317; constructing tissue engineering bone by using the marrow base cell modified by gene hBMP-4 as the seed cell.

The invention discloses a fiber pipe for a breast implant, and belongs to the field of cosmetic equipment. The fiber tube is prepared from, by mass, 6 parts of foam silicon carbide, 23 parts of polycaprolactone, 17 parts of polylactic acid, 37 parts of polyether ketone ketone, 32 parts of adipose-derived stem cell-protein hydrogel and 3 parts of dilute citric acid, the polycaprolactone and polycaprolactone are cross-linked to form porous stent, the porosity of the porous stent is 43.8%, in the adipose-derived stem cell-protein hydrogel, protein hydrogel is nano chitosan bone morphogenetic protein, the pH of the protein hydrogel is 6.4, the mass ratio of the adipose-derived stem cell to chitosan to bone morphogenetic protein is 2.3:17.2:6. Accordingly, adipose-derived stem cells can providevascular growth cells for tissue survival and growth, when the cells form a stable structure, the hydrogel structure is metabolized and decomposed, the original position becomes a cavity which can allow a blood vessel extending and development.

The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.

The invention discloses an individualized 3D (three-dimensional) printed bone tissue engineering stent with a mosaic structure. The stent is characterized in that a shape and a structure of a large area of bone defect of a jaw are rebuilt through 3D modeling. The stent comprises two parts, wherein one part is an outer outline stent used for restoring the shape and the structure of a cranio-facial bone defect, and the other part is an inner tubular stent used for promoting formation of blood vessels. The bone tissue engineering stent with the maintained shape and structure on the outer part and promoted formation of blood vessels in the inner part is formed by inoculating factors for promoting ossification, such as mesenchymal stem cells (MSCs) and / or a loaded bone morphogenetic protein (BMP), onto the outer stent, and inoculating factors for promoting the formation of the blood vessels, such as endothelial cells (ECs) and / or a loaded vascular endothelial cell growth factor (VEGF), onto the inner stent, so that stem cell proliferation, ossification differentiation, and angiopoiesis of a tissue engineering compound are facilitated, and quality and speed of osteanagenesis are improved.

Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions.

A drug for promoting bone morphogenetie protein expression to accelerate fracture healing is prepared by carboxymethylation of sodium alginate. The drug is prepared by the steps: adding 15 g of a sodium hydroxide liquid (2 mol / L) into each 100 g of sodium alginate, mixing uniformly, and stirring for 0.5 h at the temperature of 35 DEG C; then adding a mixture of 20 g of monochloroacetic acid and 20 g of sodium hydroxide according to each 100 g of sodium alginate, carrying out a stirring reaction for 3 h under a condition of the temperature of 70-80 DEG C, and thus obtaining a carboxymethyl sodium alginate resultant. The drug also can be prepared by in a 95% ethanol solution, taking sodium alginate, sodium hydroxide and monochloroacetic acid and carrying out a one-pot frying method, and particularly is prepared by the steps: according to the ratio of mass, mass and volume of 1:0.35:0.30, taking sodium alginate, sodium hydroxide and monochloroacetic acid, putting into the 95 vol% ethanol solution with the volume of 2 times that of the mixture, and carrying out a reaction under conditions of the etherification temperature of 50 DEG C and the etherification time of 3 h; and washing the reaction product with 95% ethanol, precipitating for 24 h, drying the resultant, and thus obtaining the carboxymethyl sodium alginate resultant. The obtained carboxymethyl sodium alginate is capable of promoting the bone morphogenetie protein expression, and is used in drugs for treating and preventing fractures, bone nonunion, osteonecrosis of the femoral head, and osteoporosis.

The invention belongs to the field of a biomedical material, which is mainly applied to the preparation of a compound dosage form both of bone morphogenetic protein 2 active peptide and hydroxyapatite, wherein a sequence of the bone morphogenetic protein 2 active peptide is represented by SEQ ID NO: 1-10. A preparation method provided by the invention comprises the following steps: dissolving the bone morphogenetic protein 2 active peptide into normal saline or 5% of glucose solution, and then adding a hydroxyapatite support, combining the bone morphogenetic protein 2 active peptide on the surfaces of the hydroxyapatite particles to obtain the necessary compound dosage form both of the bone morphogenetic protein and hydroxyapatite after centrifugal separation, washing and drying, so as to obtain a human hard tissue repair material provided by the invention.

There is provided a method for the simultaneous production of nephron progenitor cells and ureteric epithelial progenitor cells, comprising the step of contacting intermediate mesoderm cells with fibroblast growth factor 9 and / or fibroblast growth factor 20 , and optionally one or more selected from: bone morphogenetic protein 7; heparin; Wnt agonists; retinoic acid; The concentrations of Wnt agonist, retinoic acid and / or RA antagonist can be manipulated to favor the relative production of nephron progenitor cells and ureteric epithelial progenitor cells. The intermediate mesoderm cells are ultimately derived from human pluripotent stem cells via the posterior primitive streak stage. The nephron progenitor cells and ureteric epithelial progenitor cells may have end uses such as for kidney repair and regeneration, bioprinting of kidneys, and screening of compounds for nephrotoxicity.

A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1 / Bone Morphogenic Protein-7 (OP-1 / BMP-7) polypeptide in the renal tissue.

The invention discloses a dissoluble preparation of bone morphogenetic protein-7, which contains bone morphogenetic protein-7, L-arginine or / and urea, protein stabilizer and water for injection, and has the advantages that the solubility is high, and deposition does not occur in the serum, and the consistence can reach 0.2-1.0 mg / ml. The dissoluble preparation of bone morphogenetic protein-7 of the invention can be used for curing clinical kidney disease and vascular calcification, and for curing resumption of cerebral apoplexy, and liver and lung fibrosis as well.

The invention discloses a method of distinguishing a dorsal muscle and a tail muscle of Tilapia mossambica. The method is characterized in that a detected BMP (Bone Morphogenetic Protein) 4 antibody of Tilapia mossambica is used to detect the BMP4 proteins in the two muscle parts of Tilapia mossambica, and GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is used as a contrast to a target protein, and if proteins of 55KD are just detected, the muscle is the dorsal muscle of Tilapia mossambica.